Lenvatinib-Tislelizumab Combo Shows Promising 93% Response Rate in Rare Hereditary Kidney Cancer
• Phase 2 study demonstrates remarkable 93.3% objective response rate for lenvatinib plus tislelizumab in treating fumarate hydratase-deficient renal cell carcinoma, with 20% achieving complete response.
• The novel combination therapy shows potential as a first-line treatment for FH-RCC, a rare and aggressive form of kidney cancer that typically affects young adults in their 30s and 40s.
• While the study included only 17 patients, the preliminary safety profile appears manageable with 23.5% experiencing grade 3 or higher adverse events.
Innovative Therapies for HIV, Infertility, and Cancer Highlighted at CIIE
• Gilead Sciences has submitted a market application in China for lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, following positive Phase 3 trial results.
• Organon unveiled SJ02, a long-acting recombinant human follicle-stimulating hormone, potentially China's first, to expand fertility treatment options.
• Pfizer announced China's approval of Talazoparib for prostate cancer, targeting a genetic mutation found in 25% of patients for individualized treatment.
• Johnson & Johnson's Teclistamab Injection, the first bispecific antibody, has been approved in China for relapsed or refractory multiple myeloma.
Ruanjian Qingmai Granules Evaluated in Clinical Trial for Early Symptomatic Peripheral Artery Disease
• A multicenter, double-blind, placebo-controlled trial is underway to assess Ruanjian Qingmai granules for early symptomatic peripheral artery disease (PAD).
• The study aims to enroll 250 patients to evaluate the granules' efficacy in improving pain-free and maximum walking distance over 16 weeks.
• Ruanjian Qingmai granules, a traditional Chinese medicine formula, have shown potential in alleviating ischemic inflammation and improving lipid profiles.
• The trial will also explore the impact of the granules on inflammatory markers and quality of life in PAD patients.
© Copyright 2025. All Rights Reserved by MedPath